Published in Antimicrob Agents Chemother on February 01, 2005
Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother (2005) 1.60
Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res (2009) 1.55
Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother (2006) 1.18
Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem Rev (2014) 1.13
Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother (2006) 1.07
The search for new therapies for human cytomegalovirus infections. Virus Res (2010) 0.95
Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents. Recent Pat Antiinfect Drug Discov (2012) 0.94
Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother (2007) 0.94
Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. Antimicrob Agents Chemother (2013) 0.87
Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates. Antimicrob Agents Chemother (2008) 0.86
Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice. Antiviral Res (2006) 0.85
Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoesters. Antimicrob Agents Chemother (2006) 0.85
Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains. Antimicrob Agents Chemother (2007) 0.84
Intraocular pharmacokinetics of a crystalline lipid prodrug, octadecyloxyethyl-cyclic-cidofovir, for cytomegalovirus retinitis. J Ocul Pharmacol Ther (2011) 0.82
Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir. Antiviral Res (2006) 0.81
Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir. Bioorg Med Chem Lett (2011) 0.80
Cidofovir Activity against Poxvirus Infections. Viruses (2010) 0.80
Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection. Antimicrob Agents Chemother (2010) 0.80
Synthesis of the 5-phosphono-pent-2-en-1-yl nucleosides: a new class of antiviral acyclic nucleoside phosphonates. Bioorg Med Chem (2006) 0.79
Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug. Invest Ophthalmol Vis Sci (2011) 0.78
Evolution of an amino acid based prodrug approach: stay tuned. Mol Pharm (2013) 0.78
A modified MS2 bacteriophage plaque reduction assay for the rapid screening of antiviral plant extracts. Pharmacognosy Res (2010) 0.78
Design and synthesis of vidarabine prodrugs as antiviral agents. Bioorg Med Chem Lett (2008) 0.77
Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine. Bioorg Med Chem (2011) 0.76
Structure of cyclic nucleoside phosphonate ester prodrugs: an inquiry. J Org Chem (2011) 0.76
Antiproliferative effects of octadecyloxyethyl 9-[2-(phosphonomethoxy)ethyl]guanine against Me-180 human cervical cancer cells in vitro and in vivo. Chemotherapy (2010) 0.75
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro. Antimicrob Agents Chemother (2009) 0.75
Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother (2002) 2.59
Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother (2004) 2.45
Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol (2003) 2.35
Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res (2003) 2.34
Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother (2002) 2.34
Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology (2004) 2.32
Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet (1999) 2.24
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev (2003) 1.91
Incorporation of dietary lecithin and lysolecithin into lymph chylomicrons in the rat. J Biol Chem (1967) 1.56
Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis (2004) 1.55
Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis (2004) 1.50
Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochem Pharmacol (1993) 1.43
Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother (2004) 1.42
Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol (2004) 1.35
Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob Agents Chemother (2004) 1.30
Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs (1999) 0.98
Studies on the substrate specificity of a carboxyl ester hydrolase from human pancreatic juice. I. Action on carboxyl esters, glycerides and phospholipids. Biochim Biophys Acta (1980) 0.95
Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV. Antiviral Res (1997) 0.93
Assembly of the endoplasmic reticulum phospholipid bilayer. Transporters for phosphatidylcholine and metabolites. J Biol Chem (1987) 0.83
Alkylthioglycerol prodrugs of foscarnet: synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells. Antivir Chem Chemother (1998) 0.83
Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother (2002) 2.59
Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother (2004) 2.45
Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol (2003) 2.35
Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res (2003) 2.34
Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother (2002) 2.34
Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology (2004) 2.32
National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med (2009) 2.19
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother (2006) 1.92
In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother (2003) 1.83
Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides. J Med Chem (2004) 1.71
Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother (2005) 1.60
Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis (2004) 1.55
Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother (2003) 1.53
Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Virol (2005) 1.51
Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis (2004) 1.50
Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother (2005) 1.48
Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J Virol (2008) 1.48
National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology (2009) 1.48
Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother (2004) 1.42
Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand. Antimicrob Agents Chemother (2007) 1.41
Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J Med Chem (2006) 1.39
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother (2007) 1.38
In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antiviral Res (2006) 1.38
Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob Agents Chemother (2003) 1.37
Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections. Antimicrob Agents Chemother (2006) 1.37
Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int J Antimicrob Agents (2004) 1.35
Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol (2004) 1.35
Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity. Antiviral Res (2005) 1.31
Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob Agents Chemother (2004) 1.30
(Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. J Med Chem (2004) 1.19
Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother (2006) 1.18
Efficacy of methylenecyclopropane analogs of nucleosides against herpesvirus replication in vitro. Nucleosides Nucleotides Nucleic Acids (2003) 1.14
N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors. J Med Chem (2007) 1.13
Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob Agents Chemother (2006) 1.13
Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine (2005) 1.12
Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis (2010) 1.12
Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci (2004) 1.12
Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. J Med Chem (2005) 1.11
Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir. Invest Ophthalmol Vis Sci (2002) 1.10
Human cytomegalovirus uracil DNA glycosylase associates with ppUL44 and accelerates the accumulation of viral DNA. Virol J (2005) 1.09
A rapid DNA hybridization assay for the evaluation of antiviral compounds against Epstein-Barr virus. J Virol Methods (2007) 1.08
Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res (2004) 1.08
Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother (2006) 1.07
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol (2012) 1.06
Synthesis of cyclopentenyl carbocyclic nucleosides as potential antiviral agents against orthopoxviruses and SARS. J Med Chem (2006) 1.06
Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice. Antivir Chem Chemother (2005) 1.05
Structure-activity relationships of (S,Z)-2-aminopurine methylenecyclopropane analogues of nucleosides. Variation of purine-6 substituents and activity against herpesviruses and hepatitis B virus. J Med Chem (2003) 1.04
Virucidal activity of polysaccharide extracts from four algal species against herpes simplex virus. Antiviral Res (2009) 1.04
The enantiomers of carbocyclic 5'-norguanosine: activity towards Epstein-Barr virus. Bioorg Med Chem (2002) 1.04
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antimicrob Agents Chemother (2007) 1.03
The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons. Antimicrob Agents Chemother (2009) 1.03
Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob Agents Chemother (2006) 1.02
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob Agents Chemother (2007) 1.00
Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine (2005) 0.98
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother (2011) 0.98
9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1. J Med Chem (2006) 0.97
Determination of antiviral efficacy against lymphotropic herpesviruses utilizing flow cytometry. Antiviral Res (2003) 0.96
The search for new therapies for human cytomegalovirus infections. Virus Res (2010) 0.95
The 4',4'-difluoro analog of 5'-noraristeromycin: a new structural prototype for possible antiviral drug development toward orthopoxvirus and cytomegalovirus. Bioorg Med Chem (2005) 0.95
Combinatorial optimization of isatin-beta-thiosemicarbazones as anti-poxvirus agents. J Med Chem (2005) 0.95
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. Antimicrob Agents Chemother (2009) 0.95
Synthesis and antiviral evaluation of alkoxyalkyl esters of acyclic purine and pyrimidine nucleoside phosphonates against HIV-1 in vitro. Antiviral Res (2006) 0.94
Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother (2007) 0.94
Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir. Int J Pharm (2005) 0.94
Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2. Vaccine (2005) 0.94
Isolation and characterization of cidofovir resistant vaccinia viruses. Virol J (2008) 0.92
Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro. Mol Cancer Ther (2006) 0.92